RxDoctor Payments Data

Scott Lecroy, MD

Ophthalmology · Birmingham, ALNPI 1376563585

Payments from drug & device makers

$1,091in general payments, 2019–2025

Across 50 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$257
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$185
  • Alcon$184
  • Ocular Therapeutix, Inc.$144
  • Novartis$94
  • AbbVie$71
  • plus $156 from 5 others

What the payments were for

  • Food & beverage$1,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,091 in reported general payments places this provider in the 35th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$62,203
Medicare patients
227
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$29,308
LumiganBimatoprost26$18,196
MoxifloxacinMoxifloxacin Hcl453$17,433
Prednisolone Acetate289$15,845
RocklatanNetarsudil Mesylat/Latanoprost30$13,058
Latanoprost724$12,751
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat381$8,932
CombiganBrimonidine Tartrate/Timolol20$8,158
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$6,322
Diclofenac Sodium346$4,259
Travoprost13$2,531
Timolol Maleate143$2,528
Brimonidine Tartrate89$2,393
Bromfenac Sodium12$1,567
Epinastine Hcl15$1,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$71$55,66283 claims
Aerie Pharmaceuticals, Inc.Rocklatan$257$13,05830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →